PTHS
Pelthos Therapeutics Inc.
Biotechnology
Market Cap$15M
5Y Perf.+98.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PTHS vs AVDL
Revenue, margins, valuation, and 5-year total return — side by side.
AVDL
Avadel Pharmaceuticals plc
Drug Manufacturers - Specialty & Generic
Market Cap$2.10B
5Y Perf.+143.5%
PTHS vs AVDL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PTHS | AVDL |
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $15M | $2.10B |
| Revenue (TTM) | $7M | $249M |
| Net Income (TTM) | $-24M | $-278K |
| Gross Margin | 54.3% | 94.5% |
| Operating Margin | -300.5% | 1.8% |
| Forward P/E | — | 28.3x |
| Total Debt | $2M | $2M |
| Cash & Equiv. | $513K | $51M |
PTHS vs AVDL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PTHS
AVDL
| Stock | Jun 25 | May 26 | Return |
|---|---|---|---|
| Pelthos Therapeutic… (PTHS) | 100 | 198.4 | +98.4% |
| Avadel Pharmaceutic… (AVDL) | 100 | 243.5 | +143.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PTHS vs AVDL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: AVDL leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
PTHS
Pelthos Therapeutics Inc.
The Long-Run Compounder
PTHS is the clearest fit if your priority is long-term compounding.
- 111.9% 10Y total return vs AVDL's 99.3%
Best for: long-term compounding
AVDL
Avadel Pharmaceuticals plc
The Income Pick
AVDL carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.23
- Rev growth 5.0%, EPS growth 74.5%
- Lower volatility, beta 0.23, Low D/E 2.3%, current ratio 2.75x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AVDL | 5.0% revenue growth vs PTHS's -114.7% |
| Quality / Margins | AVDL | -0.1% margin vs PTHS's -318.4% |
| Stability / Safety | AVDL | Beta 0.23 vs PTHS's 0.68 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | AVDL | +150.5% vs PTHS's +111.9% |
| Efficiency (ROA) | AVDL | -0.2% ROA vs PTHS's -18.7% |
PTHS vs AVDL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
PTHS vs AVDL — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAVDLLAGGINGPTHS
PTHSPelthos Therapeutics …
0leads
AVDLAvadel Pharmaceutical…
4leads
6 Total Categories
CATEGORYLEADERvs PTHSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AVDL5/5
Valuation MetricsMultiples, price ratios, and targets
AVDL1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
AVDL5/5
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
AVDL2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
AVDL leads this category, winning 5 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
AVDL is the larger business by revenue, generating $249M annually — 33.6x PTHS's $7M. Profitability is closely matched — net margins range from -0.1% (AVDL) to -3.2% (PTHS).
| Metric | PTHSPelthos Therapeut… | AVDLAvadel Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $7M | $249M |
| EBITDAEarnings before interest/tax | -$21M | $8M |
| Net IncomeAfter-tax profit | -$24M | -$278,000 |
| Free Cash FlowCash after capex | -$17M | $35M |
| Gross MarginGross profit ÷ Revenue | +54.3% | +94.5% |
| Operating MarginEBIT ÷ Revenue | -3.0% | +1.8% |
| Net MarginNet income ÷ Revenue | -3.2% | -0.1% |
| FCF MarginFCF ÷ Revenue | -2.3% | +14.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +54.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -7.7% | +100.7% |
AVDL leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
AVDL leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | PTHSPelthos Therapeut… | AVDLAvadel Pharmaceut… |
|---|---|---|
| Market CapShares × price | $15M | $2.1B |
| Enterprise ValueMkt cap + debt − cash | $16M | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | -1.85x | -42.43x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 28.28x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 12.44x |
| Price / BookPrice ÷ Book value/share | — | 27.88x |
| Price / FCFMarket cap ÷ FCF | — | — |
AVDL leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
AVDL leads this category, winning 5 of 5 comparable metrics.
Profitability & Efficiency
AVDL delivers a -0.3% return on equity — every $100 of shareholder capital generates $-0 in annual profit, vs $-40 for PTHS.
| Metric | PTHSPelthos Therapeut… | AVDLAvadel Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -40.5% | -0.3% |
| ROA (TTM)Return on assets | -18.7% | -0.2% |
| ROICReturn on invested capital | — | -76.3% |
| ROCEReturn on capital employed | — | -34.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | — | 0.02x |
| Net DebtTotal debt minus cash | $2M | -$50M |
| Cash & Equiv.Liquid assets | $513,443 | $51M |
| Total DebtShort + long-term debt | $2M | $2M |
| Interest CoverageEBIT ÷ Interest expense | -12.31x | 0.66x |
AVDL leads this category, winning 5 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — PTHS and AVDL each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AVDL five years ago would be worth $27,462 today (with dividends reinvested), compared to $21,186 for PTHS. Over the past 12 months, AVDL leads with a +150.5% total return vs PTHS's +111.9%. The 3-year compound annual growth rate (CAGR) favors PTHS at 28.4% vs AVDL's 13.4% — a key indicator of consistent wealth creation.
| Metric | PTHSPelthos Therapeut… | AVDLAvadel Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -15.1% | +0.6% |
| 1-Year ReturnPast 12 months | +111.9% | +150.5% |
| 3-Year ReturnCumulative with dividends | +111.9% | +45.8% |
| 5-Year ReturnCumulative with dividends | +111.9% | +174.6% |
| 10-Year ReturnCumulative with dividends | +111.9% | +99.3% |
| CAGR (3Y)Annualised 3-year return | +28.4% | +13.4% |
Evenly matched — PTHS and AVDL each lead in 3 of 6 comparable metrics.
Risk & Volatility
AVDL leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AVDL is the less volatile stock with a 0.23 beta — it tends to amplify market swings less than PTHS's 0.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AVDL currently trades 91.8% from its 52-week high vs PTHS's 46.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PTHSPelthos Therapeut… | AVDLAvadel Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.68x | 0.23x |
| 52-Week HighHighest price in past year | $54.29 | $23.57 |
| 52-Week LowLowest price in past year | $11.20 | $8.44 |
| % of 52W HighCurrent price vs 52-week peak | +46.0% | +91.8% |
| RSI (14)Momentum oscillator 0–100 | 62.6 | 61.8 |
| Avg Volume (50D)Average daily shares traded | 11K | 0 |
AVDL leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | PTHSPelthos Therapeut… | AVDLAvadel Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $22.50 |
| # AnalystsCovering analysts | — | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.1% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
AVDL leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallAvadel Pharmaceuticals plc (AVDL)Leads 4 of 6 categories
Loading custom metrics...
PTHS vs AVDL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PTHS or AVDL a better buy right now?
Analysts rate Avadel Pharmaceuticals plc (AVDL) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PTHS or AVDL?
Over the past 5 years, Avadel Pharmaceuticals plc (AVDL) delivered a total return of +174.
6%, compared to +111. 9% for Pelthos Therapeutics Inc. (PTHS). Over 10 years, the gap is even starker: PTHS returned +111. 9% versus AVDL's +99. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PTHS or AVDL?
By beta (market sensitivity over 5 years), Avadel Pharmaceuticals plc (AVDL) is the lower-risk stock at 0.
23β versus Pelthos Therapeutics Inc. 's 0. 68β — meaning PTHS is approximately 197% more volatile than AVDL relative to the S&P 500.
04Which is growing faster — PTHS or AVDL?
On earnings-per-share growth, the picture is similar: Avadel Pharmaceuticals plc grew EPS 74.
5% year-over-year, compared to -5. 8% for Pelthos Therapeutics Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PTHS or AVDL?
Avadel Pharmaceuticals plc (AVDL) is the more profitable company, earning -28.
9% net margin versus -318. 4% for Pelthos Therapeutics Inc. — meaning it keeps -28. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AVDL leads at -25. 1% versus -300. 5% for PTHS. At the gross margin level — before operating expenses — AVDL leads at 91. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PTHS or AVDL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PTHS or AVDL better for a retirement portfolio?
For long-horizon retirement investors, Avadel Pharmaceuticals plc (AVDL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
23)). Both have compounded well over 10 years (AVDL: +99. 3%, PTHS: +111. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PTHS and AVDL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PTHS is a small-cap quality compounder stock; AVDL is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.